Mark Taratkin is an expert in Urology at Sechenov University (Russia). As of October 2026, ScienceLeadR ranks Mark Taratkin in the top 1% of experts in Russia for Prostatic Diseases and Urogenital Neoplasms. Mark Taratkin has authored 207 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 633 (community average: 125). How the SLR is computed.

LeadR Profile

Mark Taratkin Sechenov University Russia
633 ScienceLeadR Reputation 633
Network Map

Urology

Subspecialties: Nephrology - Oncology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2018 - 2026

Source: PubMed

Sechenov University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 207

Citations

Citations: 1 952 1st author: 31 Last author: 22 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The silicon stethoscope: AI's role in bridging the urological communication gap.
PMID 42704287 — urology, stethoscopes, communication
Minerva Urol Nephrol20260
Beyond satisfaction scores: quantifying communication quality in oncology care.
PMID 42174116 — communication, prostatic neoplasms
Prostate Cancer Prostatic Dis20260
How to use artificial intelligence for complex medical decisions in uro-oncology?. Considerations from the YAU-Urotechnology and Digital Health Working Group.
PMID 42132316 — intelligence, urology, artificial intelligence, digital health
Minerva Urol Nephrol20260
The data dividend: how AI turns robotic surgery into measurable value. Insight from EAU-YAU Urotechnology and Digital Health Working Group.
PMID 42023744 — urology, artificial intelligence, digital health
Minerva Urol Nephrol20260
Artificial intelligence in diagnostic, prognostic, and predictive genomic biomarkers for prostate cancer: Ready for prime time?
PMID 41483979 — genes, intelligence, neoplasms, prostate, biomarkers, prostatic neoplasms, therapeutics, genetic markers, artificial intelligence, data analysis
Urol Oncol20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 5

By status:

Unknown 4
Recruiting 1

By type:

Interventional 4
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map